{"id":"induction-without-brentuximab-vedotin","safety":{"commonSideEffects":[{"rate":null,"effect":"Unknown"}]},"_chembl":{"chemblId":"CHEMBL1742994","moleculeType":"Antibody drug conjugate"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"The exact mechanism of action is not well understood, but it is believed to work by targeting the underlying biology of lymphoma cells. Further research is needed to fully elucidate its mechanism.","oneSentence":"This drug induces a response in lymphoma patients without Brentuximab Vedotin.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T03:36:13.019Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Lymphoma"}]},"trialDetails":[{"nctId":"NCT03233347","phase":"PHASE2","title":"Doxorubicin, Vinblastine, Dacarbazine, Brentuximab Vedotin, and Nivolumab in Treating Patients With Stage I-II Hodgkin Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Academic and Community Cancer Research United","startDate":"2017-10-13","conditions":"Ann Arbor Stage I Hodgkin Lymphoma, Ann Arbor Stage IA Hodgkin Lymphoma, Ann Arbor Stage IB Hodgkin Lymphoma","enrollment":82},{"nctId":"NCT04378647","phase":"PHASE2","title":"BREntuximab Vedotin in SEcond LIne Therapy BEfore Transplant","status":"RECRUITING","sponsor":"Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea","startDate":"2020-06-01","conditions":"Hodgkin Lymphoma, Adult","enrollment":150}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":113,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["ESHAP treatment as salvage therapy"],"phase":"phase_2","status":"active","brandName":"Induction without Brentuximab Vedotin","genericName":"Induction without Brentuximab Vedotin","companyName":"Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea","companyId":"grupo-espa-ol-de-linfomas-y-transplante-aut-logo-de-m-dula-sea","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This drug induces a response in lymphoma patients without Brentuximab Vedotin. Used for Lymphoma.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}